Showing results (381-390 of 402) with videos related to
Sort By:
Pageof 41
JCO Global Oncology|February 29, 2020
Outcomes in Black and White Patients With Metastatic Renal Cell Carcinoma Treated With First-Line Tyrosine Kinase Inhibitors: Insights From Two Large CohortsDominick Bossé, Wanling Xie, Xun Lin, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 30, 2013
Fluorouracil, leucovorin, and irinotecan plus either sunitinib or placebo in metastatic colorectal cancer: a randomized, phase III trialAlfredo Carrato, Anna Swieboda-Sadlej, Marzanna Staszewska-Skurczynska, et al.Nature Communications|December 18, 2021
A targetable LIFR-NF-κB-LCN2 axis controls liver tumorigenesis and vulnerability to ferroptosisFan Yao, Yalan Deng, Yang Zhao, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2011
Changes in tumor density in patients with advanced hepatocellular carcinoma treated with sunitinibSandrine Faivre, Magaly Zappa, Valérie Vilgrain, et al.European Urology|March 1, 2016
Change in Neutrophil-to-lymphocyte Ratio in Response to Targeted Therapy for Metastatic Renal Cell Carcinoma as a Prognosticator and Biomarker of EfficacyArnoud J Templeton, Jennifer J Knox, Xun Lin, et al.Lancet (London, England)|July 19, 2025
Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trialKarim Fizazi, Arun A Azad, Nobuaki Matsubara, et al.Frontiers in Immunology|January 23, 2023
Increase of ALCAM and VCAM-1 in the plasma predicts the Alzheimer's diseaseJian Chen, An-Xiang Dai, Hai-Liang Tang, et al.European Journal of Cancer (Oxford, England : 1990)|November 1, 2024
Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: Safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 studyArun A Azad, Karim Fizazi, Nobuaki Matsubara, et al.European Urology|October 3, 2017
Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival ResultsRobert J Motzer, Alain Ravaud, Jean-Jacques Patard, et al.The New England Journal of Medicine|October 11, 2016
Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after NephrectomyAlain Ravaud, Robert J Motzer, Hardev S Pandha, et al.Pageof 41